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Summary
Objective:	Correct	subtyping	of	primary	aldosteronism	(PA)	is	essential	for	good	surgi-
cal	 outcomes.	 Adrenal	 vein	 sampling	 (AVS)	 and/or	 computed	 tomography	 (CT)	 are	
used	for	PA	subclassification.	Clinical	and/or	biochemical	improvement	after	surgery,	
however,	is	not	always	achieved	in	patients	with	presumed	unilateral	PA.	We	aimed	to	
identify	the	pitfalls	in	PA	subclassification	leading	to	surgical	treatment	failures.
Patients and Design:	We	retrospectively	studied	208	patients	who	underwent	adrenal	
vein	 sampling	 (AVS)	 for	 PA	 subclassification	 in	 a	 tertiary	 referral	 centre,	 between	
January	2009	and	August	2016.	Simultaneous	bilateral	AVS	was	performed	before	
and	after	cosyntropin	administration.	We	implemented	immunohistochemistry	for	al-
dosterone	synthase	(CYP11B2)	and	17α-	hydroxylase/17,20	lyase	(CYP17A1)	in	adre-
nal	glands	resected	from	patients	without	improvement	of	PA	after	surgical	treatment	
and	from	those	with	limitations	in	AVS	interpretation.
Results:	Of	55	patients	who	underwent	adrenalectomy,	three	(5.5%)	had	no	improve-
ment	 of	 PA.	 All	 three	 patients	 underwent	 partial	 adrenalectomy	 to	 remove	 a	 CT-	
detected	nodule	present	on	the	same	side	with	AVS	lateralization.	Immunohistochemistry	
revealed	a	CYP11B2-	negative	nodule	in	both	cases	available.	All	patients	who	under-
went	total	adrenalectomy	based	on	AVS	lateralization	benefitted	from	surgery,	includ-
ing	three	patients	with	unilateral	unsuccessful	AVS	and	aldosterone	suppression	in	the	
catheterized	side	vs	inferior	vena	cava.
Conclusions:	Radiographically	 identified	adrenal	nodules	are	not	always	a	source	of	
PA,	even	when	ipsilateral	with	AVS	lateralization.	These	data	caution	against	reliance	
on	imaging	findings,	either	alone	or	in	conjunction	with	AVS,	to	guide	surgery	for	PA.
K E Y W O R D S
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1  | INTRODUCTION
Primary	aldosteronism	(PA)	 is	the	most	common	identifiable	form	of	
secondary	hypertension.1	PA	is	highly	prevalent	among	patients	with	
resistant	hypertension	and	 is	diagnosed	 in	over	10%	of	the	patients	
referred	 to	 specialized	 centres.2-4	 PA	 is	 associated	 with	 increased	
cardiovascular	 morbidity	 and	 mortality	 as	 compared	 to	 equivalent	
	degrees	 of	 essential	 hypertension,5-7	 and	 hence,	 early	 recognition	
and	treatment	of	PA	is	imperative.8	PA	is	traditionally	subclassified	as	
either	 bilateral	 hyperaldosteronism	 (BHA)	 or	 aldosterone	 producing	Richard	J.	Auchus	and	Adina	F.	Turcu	contributed	equally	to	this	work.
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adenomas	(APA),1	although	some	patients	have	features	of	both	sub-
types.	 Correct	 subclassification	 of	 PA	 is	 essential,	 as	 patients	 with	
unilateral	 PA	 can	 benefit	 from	 surgical	 treatment.	 Immunostaining	
for	aldosterone	synthase	(CYP11B2),	the	key	enzyme	in	aldosterone	
production,	is	not	widely	available;	consequently,	when	postoperative	
clinical	assessment	demonstrates	surgical	cure	of	hyperaldosteronism,	
it	 is	assumed	that	a	histologically	 identified	macroscopic	adrenal	 tu-
mour	was	the	primary	source	of	aldosterone.	Since	the	development	
of	highly	specific	CYP11B2	antibodies,	it	has	been	demonstrated	that	
the	subclassification	of	PA	spans	a	continuum,	ranging	from	single	or	
multiple	APA,	to	small	aldosterone	producing	cell	clusters	(APCC),	to	
zona	glomerulosa	hyperplasia.9-12	The	variable	immunohistochemistry	
findings	 in	 resected	 adrenals	 from	patients	with	 PA	 underscore	 the	
limitations	of	adrenal	 imaging	 in	 identifying	the	source(s)	of	aldoste-
rone	excess.
Adrenal	 vein	 sampling	 (AVS)	 is	 considered	 the	 most	 accurate	
method	 for	 determining	whether	 one	 or	 both	 adrenals	 produce	 ex-
cess	 aldosterone.8	 Aside	 from	 patients	 younger	 than	 35	years	with	
unequivocal	 PA,13,14	 cross-	sectional	 adrenal	 imaging	 findings	 are	
frequently	 discordant	with	 the	 aldosterone	 source	 as	 lateralized	 by	
AVS.15-19	 Nevertheless,	 resolution	 of	 PA	 after	 unilateral	 adrenalec-
tomy	 is	 not	 always	 achieved,	 even	 if	 the	 decision	 is	 based	 on	AVS	
lateralization,9,13,20	in	part	because	AVS	technique	and	interpretation	
vary	widely	between	centres.21	Moreover,	AVS	results	might	be	influ-
enced	by	several	antihypertensive	agents	and	by	autonomous	adrenal	
cortisol	synthesis.1,8	For	these	reasons,	 the	supremacy	of	AVS	 in	PA	
subclassification	has	been	questioned.20
Several	studies	have	focused	on	outcomes	after	adrenalectomy	in	
PA,	but	the	emphasis	has	been	on	success	rates	rather	than	on	causes	
of	 treatment	 failure.	While	 clinical	 improvement	 is	 achieved	 in	 the	
majority	of	PA	cases	treated	surgically,9,13,22-24	data	regarding	contrib-
utors	 to	 surgical	 treatment	 failure	 have	been	 scarce.	 In	 the	 present	
study,	we	aimed	to	identify	the	pitfalls	in	PA	subclassification,	leading	
to	the	absence	of	PA	improvement	after	surgical	treatment.
2  | PATIENTS AND METHODS
2.1 | Study participants
In	 our	 centre,	 all	 patients	 with	 PA	 considered	 for	 surgical	 treat-
ment	undergo	AVS.	We	studied	patients	who	underwent	AVS	at	the	
University	of	Michigan	between	1	January	2009	and	31	August	2016.	
Patient	demographics,	laboratory	results,	computed	tomography	(CT)	
imaging,	 AVS	 data,	 pathology	 reports	 and	 postoperative	 follow-	up	
records	were	 retrospectively	 reviewed.	 The	 antihypertensive	medi-
cations	were	converted	to	a	standardized	daily	defined	dose	 (DDD)	
according	 to	 the	 WHO	 ATC/DDD	 Index.25	 Immunohistochemistry	
studies	 were	 conducted	 on	 paraffin-	embedded	 adrenal	 tissues	 in	
a	 subset	of	patients,	 as	detailed	below.	All	 studies	were	 conducted	
under	University	of	Michigan	 Internal	Review	Board	 (IRB)	approved	
protocols.	A	waiver	of	consent	was	granted	for	the	retrospective	stud-
ies;	adrenal	tissue	experiments	were	conducted	after	obtaining	writ-
ten	informed	consent	from	all	participants.
2.2 | Clinical assessment
Plasma	 aldosterone	 concentration	 (PAC)	 and	 plasma	 renin	 activ-
ity	 (PRA)	 were	 measured	 for	 case	 detection	 of	 PA,	 and	 screening	
was	positive	in	164/170	(96.5%)	of	patients,	based	on	a	PAC	(ng/L)/
PRA	 (μg/L/h)	 ratio	 (ARR)	≥200,	PAC	>100	ng/L	and	PRA	<1	μg/L/h.	
In	125/170	 (73.5%)	patients,	 the	diagnosis	was	confirmed	based	on	
oral	 sodium	 loading	 test	 (followed	by	a	24-	hour	urinary	aldosterone	
>12	μg),	 saline	 infusion	 test	 (PAC	 >100	ng/L	 at	 4	hours),	 or	 a	 sup-
pressed	PRA	(<1.0	μg/L/h)	with	spontaneous	hypokalaemia	and	PAC	
>200	ng/L.8	 Six	 patients	 with	 a	 high	 clinical	 index	 of	 suspicion	 did	
not	meet	ARR	screening	criteria	but	were	included	due	to	inability	to	
discontinue	 interfering	 medications.	 PAC	 was	 measured	 by	 a	 com-
petitive	 chemiluminescent	 immunoassay	 on	 the	DiaSorin	 Liaison	XL	
analyzer;	the		coefficient	of	variability	 (CV)	was	8.9%-	9.4%.	PRA	was	
determined	using	a	radioimmunoassay	for	angiotensin	I	manufactured	
by	DiaSorin,	with	a	CV	between	13.0%	 (at	2.3	μg/L/h)	and	8.6%	 (at	
5.8 μg/L/h).	 Serum	 cortisol	 was	 measured	 by	 a	 competitive	 chemi-
luminescent	 immunoassay	 on	 a	 Siemens	 ADVIA	 Centaur	 analyzer,	
with	CV	of	5.1%-	7.1%.	Urinary	aldosterone	was	measured	by	 liquid	
chromatography-	tandem	 mass	 spectrometry	 (LC-	MS/MS)	 at	 Mayo	
Medical	Laboratories.
Because	patients	with	unilateral	dominance	of	PA	might	still	have	
milder	 autonomous	 aldosterone	 production	 from	 the	 contralateral	
side,	we	focused	on	patients	with	lack	of	PA	improvement	after	sur-
gery,	 rather	 than	 on	PA	 cure.	The	 absence	 of	 PA	 improvement	was	
defined	 as:	 postoperative	 PRA	 <1	μg/L/h	 and	 PAC	 fall	 by	 <50%	 as	
compared	to	the	preoperative	value.
2.3 | Adrenal vein sampling
Adrenal	vein	sampling	was	performed	by	one	of	two	experienced	in-
terventional	radiologists	at	the	University	of	Michigan.	Samples	were	
obtained	simultaneously	from	the	inferior	vena	cava	(IVC)	and	both	ad-
renal	veins	(AV)	before	and	10-	30	minutes	after	0.25	mg	cosyntropin	
administration	(minimum	three	time	points).	Cosyntropin	was	injected	
as	a	0.125	mg	bolus	followed	by	continuous	infusion	(0.75	mg/h	prior	
to	November	2014,	and	0.125	mg/h	 thereafter).	AV	catheterization	
was	 considered	 successful	 when	 the	 selectivity	 index	 (SI),	 defined	
by	the	AV/IVC	cortisol	concentrations,	was	≥2	prior	to	and	≥5	after	
cosyntropin	administration,	respectively.	The	lateralization	index	(LI),	
defined	as	the	aldosterone/cortisol	ratio	between	the	two	AVs,	and	
contralateral	index	(CI),	defined	as	(aldosterone/cortisol)nondominant	AV/
(aldosterone/cortisol)IVC	were	used	to	assess	lateralization.	Unilateral	
PA	was	diagnosed	if	the	LI	was	≥2	before	and	≥4	after	cosyntropin	ad-
ministration,	respectively.	A	CI	<1	defined	contralateral	suppression.
2.4 | Immunohistochemistry
We	 assessed	 the	 aldosterone	 synthetic	 capacity	 of	 the	 surgically	
	removed	 adrenal	 tissue	 in	 patients	 who	 failed	 surgical	 treatment	
and	 in	patients	with	unsuccessful	 access	of	one	AV.	Localization	of	
CYP11B2	 and	 17α-	hydroxylase/17,20	 lyase	 (CYP17A1,	 an	 enzyme	
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involved	 in	 glucocorticoid	 and	 androgen	 synthesis)	 expressing	 cells	
was	 assessed	 by	 immunohistochemistry,	 using	 corresponding	 anti-	
human	antibodies	(anti-	CYP11B2,	mouse;	1:1500,	Millipore,	Billerica,	
MA,	 USA,	 #MABS1251;	 anti-	CYP17A1,	 rabbit;	 1:1000,	 kindly	 pro-
vided	by	Dr.	Michael	R.	Waterman,	Vanderbilt	University	School	of	
Medicine,	Nashville,	TN,	USA),	as	previously	described.10,26
2.5 | Statistical analysis
Statistical	differences	in	measured	parameters	between	groups	were	
evaluated	using	the	Mann-	Whitney	U-	test.	A	P value < .05	was	con-
sidered	significant.
3  | RESULTS
3.1 | Demographic and diagnostic data
Between	 January	 2009	 and	August	 2016,	 208	 patients	 underwent	
AVS	 in	 our	 centre.	Of	 these,	 38	 patients	 referred	 directly	 to	 AVS,	
without	clinical	records	available	for	review,	were	excluded	(Figure	1).	
Of	the	remaining	170	patients,	101	(59%)	were	men.	The	median	age	
of	 all	 participants	was	54	 (range,	30-	79).	AVS	was	 considered	 suc-
cessful	(based	on	SI	criteria	defined	in	Methods)	in	122	(72%)	and	159	
patients	 (94%)	before	and	after	cosyntropin	administration,	 respec-
tively	 (Figure	1).	Unilateral	PA	was	diagnosed	 in	66/122	 (54%)	 and	
87/159	(55%)	patients	before	and	after	cosyntropin	administration,	
respectively.	Contralateral	 suppression	was	present	 in	50/66	 (75%)	
patients	and	82/87	(94%)	patients	with	unilateral	PA	before	and	after	
cosyntropin	administration,	respectively.	In	total,	16	of	the	159	(10%)	
successfully	 catheterized	 patients	 had	 discordant	 lateralization	 be-
fore	 vs	 after	 cosyntropin	 administration.	 In	 five	 patients,	 unilateral	
PA	was	apparent	only	before	cosyntropin,	while	11	other	patients	lat-
eralized	only	after	cosyntropin	administration	(Figure	1).	No	patients	
had	opposite	lateralization	based	on	pre-	vs	postcosyntropin	LI.
Because	 catheterization	 is	 less	 often	 successful	 without	 co-
syntropin	administration,	AVS	data	after	cosytropin	administration	
have	been	preferentially	 used	 for	 clinical	 decisions	 in	 our	 centre,	
and	PA	will	 be	 further	 referred	 to	 as	 unilateral	 or	 bilateral	 based	
on	these	results,	unless	otherwise	specified.	 In	unilateral	PA,	me-
dian	PAC	(330	ng/L	vs	220	ng/L,	P < .001)	and	ARR	(1970	vs	870,	
P < .001)	were	 higher,	 and	 PRA	was	 lower	 (0.1	μg/L/h	vs	 0.3	μg/
L/h,	P = .007)	than	in	bilateral	PA	(Table	1).	Hypokalaemia	was	more	
frequent	 in	 patients	with	 unilateral	 PA	 (97%)	 than	 in	 those	with	
bilateral	PA	(75%).
Adrenal	CT	was	 performed	 in	 158	patients	 (Figure	2).	Unilateral	
adrenal	 abnormalities	 were	 diagnosed	 in	 114/158	 (72%)	 patients:	
single	nodule	 in	93	patients;	multiple	nodules	 in	 two	patients;	nod-
ules	and	underlying	hyperplasia	in	four	patients;	unilateral	thickening	
alone	in	15	patients.	Bilateral	adrenal	nodules	and/or	hyperplasia	were	
observed	 in	24	patients	 (15%).	CT	findings	coincided	with	the	 later-
alization	determined	by	AVS	 in	80/158	(51%)	patients	 (Figure	2).	Of	
117	patients	with	adrenal	nodules,	51	patients	were	evaluated	for	au-
tonomous	cortisol	 synthesis;	 five	patients	had	a	 cortisol	>50	nmol/l	
after	 1	mg	dexamethasone	 suppression	 test.	Of	 these	 five	 patients,	
two	lateralized	on	the	same	side	with	the	nodule,	suggesting	cortisol	
F IGURE  1 Adrenal	vein	sampling	
(AVS)	data.	Adrenal	vein	catheterization	
was	considered	successful	when	
selectivity	index	(SI)	was	≥2	before	and	
≥5	after	cosyntropin	administration.	
Unilateral	PA	was	diagnosed	if	lateralized	
index	(LI)	was	≥2	before	and	≥4	after	
cosyntropin	administration.	B/L,	bilateral.	
*Classification	based	on	postcosyntropin	
data.	Uni,	unilateral;	Bi,	bilateral;	Failed,	
failure	of	adrenal	vein	catheterization.	
+In	this	patient,	AVS	data	suggested	clear	
lateralization	and	contralateral	suppression	
prior	to	cosyntropin	stimulation,	but	
bilateral	PA	after	cosyntropin
TABLE  1 Clinical	and	biochemical	characteristics	of	study	participants
Unilateral PA 
N = 87
Bilateral PA 
N = 72
Sex(M/F) 55	(63%)/32	(37%) 40	(56%)/32	(44%)
Age 53	(30-	78) 56	(31-	79)
BMI 34	(20-	54) 33	(23-	56)
Hypokalaemia	(%) 97% 75%
No.	of	antihypertensive	
agents	(0/1/2/3/4/5+)
1/4/19/11/8/44 2/10/9/17/18/16
Basal	PAC	(ng/L)a 330* [210- 460] 220 [160- 290]
Basal	PRA	(μg/L/h)a 0.1** [0.1- 0.4] 0.3 [0.1- 0.6]
PAC,	plasma	aldosterone	concentration;	PRA,	plasma	renin	activity.
Classification	based	on	postcosyntropin	data.	BMI,	body	mass	index.
aData	are	expressed	as	medians	[interquartile	range].
*P < .001	vs	bilateral	PA.
**P < .01	vs	bilateral	PA.
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co-	secretion	from	the	ipsilateral	side;	two	had	bilateral	PA,	and	in	one	
patient	AVS	was	unsuccessful.
3.2 | Postsurgical outcomes
In	 total,	 55	 (32%)	 patients	 underwent	 unilateral	 adrenalectomy,	
	either	 total	 (52)	 or	 partial	 (3).	 Of	 the	 remaining	 37	 patients	 with	
unilateral	PA,	24	were	subsequently	managed	at	other	 institutions,	
and	 in	 the	 other	 13	 patients,	 surgery	 was	 postponed	 for	 various	
reasons,	 including	 physician’s	 recommendations	 or	 personal	 pref-
erence.	Postoperative	 follow-	up	 ranged	 from	5	days	 to	20	months	
(median	 20	days).	 Postoperative	 clinical	 assessment	 and	 informa-
tion	regarding	antihypertensive	medications	was	available	in	all	but	
two	patients,	while	hormonal	follow-	up	was	performed	in	38	(69%)	
patients.
Of	55	patients	treated	surgically,	three	had	no	improvement	of	PA	
(Table	2).	All	three	patients	demonstrated	lateralization	of	PA	based	on	
AVS.	CT	showed	one	adrenal	nodule	on	the	dominant	side	in	all	three	
patients;	an	additional	subcentimetre	nodule	and	lentiform	thickening	
of	the	contralateral	gland	was	observed	in	one	patient.	Intraoperative	
ultrasound	was	performed	in	two	of	the	patients	and	detected	a	single	
nodule	on	the	side	with	AVS	 lateralization.	All	 three	patients	under-
went	partial	adrenalectomy,	removing	the	area	of	the	gland	containing	
the	nodule	identified	on	imaging.	The	clinical	pathology	report	noted	
an	adrenocortical	adenoma	in	all	three	cases.
Adrenalectomy	was	performed	in	four	patients	in	whom	AVS	had	
failed	on	one	 side,	 three	with	an	aldosterone/cortisol	 ratio	 lower	 in	
the	successfully	catheterized	side	than	in	IVC.	All	four	patients	experi-
enced	resolution	of	PA	and	a	decline	in	the	ATC/DDD	index.
3.3 | Immunohistochemistry
To	understand	 the	 pathophysiology	 of	 poor	 clinical	 outcomes	 after	
adrenalectomy,	as	well	as	successful	outcomes	in	cases	with	incom-
plete	 AVS	 data,	 we	 performed	 immunohistochemical	 staining	 for	
CYP11B2	 on	 the	 adrenal	 glands	 from	 patients	 who	 failed	 surgical	
treatment	 (two	patients;	 for	 the	 third,	 pathology	 specimen	was	not	
available)	and		patients	in	whom	AVS	failed	unilaterally	(four	patients).
In	the	two	patients	with	available	pathology	specimens	who	had	
failed	surgical	 treatment,	 the	cortical	adenomas	 removed	were	neg-
ative	for	CYP11B2,	while	the	entire	tissue	was	diffusely	positive	for	
CYP17A1	(Figure	3,	A	and	B,	Cases	2	and	3	in	Table	2).	These	results	
demonstrated	that	despite	AVS	lateralization,	the	largest	nodule	was	
not	the	cause	of	PA	 in	these	patients.	One	of	these	patients	under-
went	a	second	AVS,	which	again	demonstrated	lateralization	of	PA	to	
the	partial	adrenalectomy	side.	CT-	guided	radiofrequency	ablation	of	
the	 remnant	adrenal	 tissue	was	performed,	with	subsequent	 resolu-
tion	of	PA	(PAC	fell	from	336	ng/L	to	56	ng/L),	decline	of	ATC/DDD	
index	and	resolution	of	hypokalaemia.
Of	the	four	patients	with	unilateral	AVS	failure	who	underwent	uni-
lateral	adrenalectomy,	CYP11B2	staining	localized	to	the	macroscopic	
nodule	in	three.	In	the	fourth	patient,	however,	the	CT-	detected	nod-
ule	was	negative	for	CYP11B2	and	positive	for	CYP17A1,	while	an-
other,	smaller,	nodular	structure	showed	positive	CYP11B2	and	weak	
CYP17A1	expression,	 suggesting	 that	 the	 source	of	 excess	 aldoste-
rone	production	was	the	smaller	nodule	rather	than	the	one	identified	
on	CT	(Figure	3C).
4  | DISCUSSION
Adrenal	vein	sampling	has	been	widely	accepted	as	the	“gold	stand-
ard”	 for	 lateralization	of	PA.8,16,27	The	basis	 for	 recommending	AVS	
in	 all	 patients	with	 PA	 older	 than	 35	who	might	 consider	 surgery8 
has	emerged	from	numerous	studies	demonstrating	poor	correlation	
of	 AVS	 with	 cross-	sectional	 imaging.13,14,16	 Previous	 studies	 have	
largely	focused	on	success	rates	after	adrenalectomy,	but	the	cases	
with	 absent	 clinical	 benefit	 after	 surgery	have	been	poorly	 studied.	
Published	data	suggest	that	both	CT	and	AVS	are	imperfect	tools	for	
PA	subclassification.13,20	In	the	present	study,	we	sought	to	identify	
F IGURE  2 Comparison	between	 
CT	findings	and	AVS	lateralization.	 
*	Classification	based	on	post-cosyntropin	
data
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parameters	associated	with	poor	outcomes	after	surgical	treatment	in	
PA	patients	guided	with	both	AVS	and	CT	data.
Of	all	surgically	treated	cases,	the	only	ones	without	PA	improve-
ment	were	 three	 patients	who	 underwent	 partial	 adrenalectomy	 to	
remove	an	adrenal	nodule	demonstrated	by	CT	 imaging	on	the	 ipsi-
lateral	side	with	AVS	 lateralization.	Staining	for	CYP11B2	was	nega-
tive	in	both	patients	with	available	pathology	specimens,	emphasizing	
that	a	prominent	nodule	is	not	always	the	source	of	aldosterone,	even	
when	present	on	 the	 ipsilateral	 side	with	AVS	 lateralization.	One	of	
the	patients	experienced	PA	resolution	after	radiofrequency	ablation	
of	the	remnant	adrenal	gland,	consistent	with	the	AVS	results.	Failure	
of	PA	resolution	has	been	previously	reported	 in	2/29	patients	with	
partial	adrenalectomy,24	although	other	groups	reported	no	difference	
in	clinical	outcomes	between	patients	who	underwent	total	or	partial	
adrenalectomy.23,28	Using	CYP11B2	immunostaining,	we	further	show	
that	in	some	patients	with	unilateral	PA,	the	source	of	aldosterone	ex-
cess	includes	neoplastic	cells	outside	of	a	dominant	nodule,	as	other	
investigators	 have	 reported.9,29	Moreover,	 adrenal	 CT	 abnormalities	
can	be	contralateral	to	the	side	suggested	by	AVS	as	the	source	of	au-
tonomous	aldosterone	production.13,16	Taken	together,	 these	 results	
suggest	 that	while	macroscopic	APAs	are	more	common	 than	other	
types	of	unilateral	PA,	surgical	planning	cannot	be	reliably	based	on	
CT	findings.
Next,	we	investigated	potential	sources	of	error	 in	AVS	interpre-
tation.	AVS	technique	and	criteria	for	successful	catheterization	and	
lateralization	 vary	 widely	 among	 centres.21,30,31	 In	 our	 institution,	
samples	 are	 routinely	 obtained	 both	 before	 and	 after	 cosyntropin	
stimulation.	The	 rate	 of	 successful	 catheterization	 in	 our	 institution	
using	the	stated	SI	criteria	is	considerably	higher	when	cosyntropin	is	
used	(94%	vs	72%),	even	in	the	hands	of	experienced	interventional	
radiologists,	in	agreement	with	the	experiences	reported	by	other	cen-
tres.32,33	The	proportion	of	uni-	vs	bilateral	PA	was	comparable	before	
and	 after	 cosyntropin	 administration,	 although	 10%	 of	AVS	 studies	
yielded		discrepant	results.	In	total,	6/16	patients	with	discordant	pre-	
vs	 postcosyntropin	AVS	 lateralization	 had	 adrenalectomy:	 one	who	
lateralized	only	before	and	five	who	lateralized	only	after	cosyntropin.	
Of	 these,	 only	 one	 patient—whose	 surgery	was	 a	 partial	 adrenalec-
tomy—did	not	have	improvement	of	PA	after	surgery.	In	a	recent	study	
of	175	patients	who	underwent	AVS	at	another	tertiary	referral	centre,	
the	lateralization	index	was	discordant	in	28%	of	cases,	the	majority	
of	which	lateralized	only	prior	to	cosyntropin	administration.32	Taken	
together,	these	data	suggest	that	lateralization	under	any	AVS	proto-
col	is	a	strong	predictor	of	clinical	improvement	after	surgery,	even	if	
lateralization	is	not	present	under	all	tested	conditions.
Adrenalectomy	 was	 performed	 in	 three	 patients	 with	 unilateral	
AVS	 failure	 but	who	demonstrated	 suppression	 of	 aldosterone	 pro-
duction	in	the	successfully	catheterized	side	as	compared	to	IVC.	All	
three	 patients	 experienced	 resolution	 of	 PA	 and	 reduction	 in	 their	
antihypertensive	regimen.	These	outcomes	suggest	that	unilateral	al-
dosterone	suppression	alone	is	a	strong	indicator	of	contralateral	dom-
inance	in	PA	and	that	AV/IVC	aldosterone	suppression	can	be	utilized	
as	a	decision	tool	when	AVS	fails	unilaterally.	Our	results	substantiate	
previous	reports	of	favourable	outcomes	in	patients	with	unilateral	PA	T
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F IGURE  3 Histopathological	findings	of	
selected	adrenal	tissue	(A	and	B):	Adrenal	
nodules	resected	from	patients	who	
underwent	selective	resection	of	a	CT-	
detected	nodule	(Cases	2	and	3,	Table	2).	
Both	nodules	demonstrated	no	CYP11B2	
expression,	while	CYP17A1	was	positive	
in	the	nodules.	(C)	Adrenal	tissue	resected	
from	a	patient	who	had	unilaterally	
unsuccessful	AVS.	The	CT-	detected	
nodule	was	negative	for	CYP11B2,	while	
another	smaller	nodule	had	CYP11B2	
expression.	[Colour	figure	can	be	viewed	at	
wileyonlinelibrary.com]
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and	contralateral	suppression.34-36	As	was	previously	observed,37 we 
found	that	contralateral	suppression	was	more	frequent	post-	as	com-
pared	to	precosyntropin	administration.	These	results,	along	with	the	
favourable	surgical	outcomes	in	such	patients,35-37	suggest	that	cosyn-
tropin	 does	 not	 often	disproportionately	 stimulate	 aldosterone	pro-
duction	from	the	contralateral	adrenal	 in	unilateral	PA.	Nonetheless,	
this	aspect	requires	further	elucidation	by	both	 in	vitro	experiments	
and	prospective	clinical	trials.
While	 several	 caveats	 in	 AVS	 technique	 and	 interpreta-
tion13,15,21,38,39	 require	 further	 clarification,	 we	 have	 not	 identified	
any	cases	with	absent	clinical	benefit	after	AVS-	guided	total	adrenal-
ectomy.	The	 superiority	of	AVS	 in	PA	has	been	 recently	questioned	
by	Dekkers	and	colleagues,	who	randomly	assigned	200	patients	with	
PA	to	undergo	subclassification	by	either	CT	or	AVS.20	At	1-	year	fol-
low-	up,	 there	 was	 no	 statistical	 difference	 in	 the	 antihypertensive	
treatment	 intensity	 between	 the	 two	 groups,	 despite	 the	 fact	 that	
the	agreement	between	AVS	and	CT	findings	was	only	50%.	Of	 the	
92	patients	(46	in	each	group)	who	underwent	surgery,	PA	was	per-
sistent	 in	nine	 (20%)	vs	 five	 (11%)	patients	with	CT-	or	AVS-	guided	
surgery,	respectively.	These	failure	rates	are	much	higher	than	in	other	
reports.11,13,22	Nonetheless,	 the	 study	was	 underpowered	 to	 detect	
a	 difference	 in	 failure	 rates	 after	 AVS	 or	 CT-	guide	 adrenalectomy.	
Furthermore,	MRA	use	was	permitted	postoperatively,	allowing	blood	
pressure	control	in	uncured	patients	from	both	groups.40
Similar	to	previous	reports,	the	concordance	between	AVS	and	CT	
findings	in	our	study	was	only	53%	and	highest	in	cases	with	single	ad-
renal	nodules.	Moreover,	unilateral	PA	was	diagnosed	by	AVS	in	35%	
of	patients	with	no	detectable	adrenal	abnormalities	by	CT,	and	all	of	
these	patients	benefited	clinically	from	adrenalectomy.	These	results	
reinforce	 that,	 in	contrast	 to	cases	of	hypercortisolism,	autonomous	
aldosterone	synthesis	from	a	small	group	of	highly	efficient	cells	might	
be	sufficient	 to	cause	disease.	Multiple	adrenocortical	micronodules	
or	diffuse	hyperplasia	of	the	zona	glomerulosa	has	been	described	in	
such	patients.12	Taken	together,	these	results	suggest	that	over	a	third	
of	patients	with	PA	could	be	denied	the	opportunity	of	surgical	treat-
ment	if	subtyping	was	based	on	cross-	imaging	studies.
In	summary,	we	explored	the	reasons	behind	surgical	failure	and	
the	pitfalls	of	the	commonly	used	PA	subclassification	tools,	CT	and	
AVS.	Among	the	strengths	of	our	study	are	the	large	numbers	of	pa-
tients	captured	within	a	tertiary	referral	adrenal	centre	and	the	routine	
collection	of	serum	both	before	and	after	cosyntropin	administration	
during	AVS.	Most	importantly,	implementing	CYP11B2	immunostain-
ing,	we	 demonstrated	 that	 autonomous	 aldosterone	 synthesis	 does	
not	always	correspond	with	radiological	findings,	even	when	ipsilateral	
AVS	lateralization	is	present.	Consequently,	our	data	caution	against	
reliance	on	cross-	sectional	imaging	as	a	criterion	for	PA	lateralization	
or	 guide	 for	 adrenalectomy.	The	 limitations	 to	 our	 data	 include	 the	
retrospective	design	and	the	number	of	patients	who	did	not	undergo	
surgery.	 In	addition,	postsurgical	evaluation	was	heterogeneous	and	
relatively	limited,	making	it	unfeasible	to	assess	a	range	of	outcomes.	
Carefully	planned	prospective	studies,	 incorporating	uniform	criteria	
for	postoperative	 follow-	up,	 remain	necessary	 to	 clarify	 the	optimal	
approach	to	PA	lateralization	in	cases	amenable	to	surgical	treatment.
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